Request for Nominations for Candidates To Serve on the National Public Health Surveillance and Biosurveillance Advisory Committee (NPHSBAC), 69628 [2012-28172]
Download as PDF
<![CDATA[
69628
Federal Register / Vol. 77, No. 224 / Tuesday, November 20, 2012 / Notices
ORI found that the Respondent
engaged in research misconduct by
falsifying and/or fabricating data that
were included in ten (10) published
papers, one (1) submitted manuscript,
seven (7) grant applications, and three
(3) progress reports over a period of ten
(10) years. Respondent reported
experimental data for knockout mice
that did not exist in five (5) grant
applications and three (3) progress
reports and also falsified and/or
fabricated images in 45 figures included
in the following:
• J. Biol. Chem. 277(7):4925–31, 2002
• Am J. Physiol. Cell Physiol. 291(6):C1271–
8, 2006
• Am J. Physiol. Cell Physiol. 294(1):C295–
305, 2008
• J. Lipid Res. 42:1444–1449, 2001
• J. Biol. Chem. 275:25595, 2000
• J. Biol. Chem. 277(26):23525–33, 2002
• Proc. Natl. Acad. Sci. USA 101(10):3450–
5, 2004
• J. Biol. Chem. 280(33):29543–50, 2005
• J. Biol. Chem. 273:6525–6532, 1998
• Am J. Physiol. Cell Physiol. 282:C935–46,
2002
• ‘‘Effects of HIV protease and nucleoside
reverse transcriptase inhibitors on
macrophage cholesterol accumulation in
humans,’’ submitted August 6, 2008
• R01 HL078976–01
• R01 HL078979–01A1
• R01 DK063025–01A2
• R01 HL088150–01
• U54 CA116853–01
• R01 HL093155–01
• R01 HL068509–01A1
• Progress reports HL078976–02, –03, and
–04.
wreier-aviles on DSK5TPTVN1PROD with
As a result of its investigation, UK
recommended that the publication(s)
listed above be retracted or corrected.
Specifically, ORI finds that
Respondent:
• Falsely reported in Figure 14 and
associated text in NIH grant applications R01
HL07897601 and –01A1 that experiments
were performed to determine if endothelialspecific caveolin-1 null mice were protected
from saturated fatty acid-induced
atherosclerosis, when these mutant mice did
not exist in the laboratory at the time; Dr.
Smart also falsely reported the use of these
mice in related progress reports R01
HL078976–02, –03, and –04 and in three (3)
additional NIH grant applications: Figure 11
in R01 HL088150–01, Figure 11 in U54
CA116853, and Figure 9 in DK063025–01A2
• Falsified and/or fabricated images in NIH
grant application R01 HL078976–01A1 by
duplicating and altering bands in 14 Western
blot images and one (1) RT–PCR image
included in Figures 3, 6, 11, 12, 13, 14, and
15; false Western blots were also included in
the earlier version of the grant application
R01 HL078976–01, Figures 3, 6, 11, 13, and
14
• Falsified and/or fabricated Western blots
and one (1) RNase protection assay by
duplicating and altering bands in thirty-three
(33) figures included in ten (10) published
VerDate Mar<15>2010
15:12 Nov 19, 2012
Jkt 229001
papers, one (1) submitted manuscript, and
two (2) NIH grant applications. Specifically,
false or fabricated images were included in:
< Figures 5 and 7, J. Biol. Chem.
277(7):4925–31, 2002
< Figure 4B, Am J. Physiol. Cell Physiol.
291(6):C1271–8, 2006
< Figures 2A, 3A, 6A, and 7A, Am J.
Physiol. Cell Physiol. 294(1):C295–305, 2008
< Figures 3, 5, and 6, J. Lipid Res.
45:1444–1449, 2001
< Figure 2A, J. Biol. Chem. 275(33):25595–
99, 2000
< Figures 2A/B/C and 4A/B, J. Biol. Chem.
277(26):23525–33, 2002
< Figures 2B/D and 4, Proc. Natl. Acad.
Sci. USA 101(10):3450–5, 2004
< Figures 1A and 5B, J. Biol. Chem.
280(33):29543–50, 2005
< Figures 1A, 2A/B, and 4A, J. Biol. Chem.
273:6525–6532, 1998
< Figure 1B, Am J. Physiol. Cell Physiol.
282:C935–46, 2002
< Figures 2A, 4, 6B, 7, and 8 in a
submitted manuscript
< Figures 7A, 8A, 9A, and 10B in grant
application HL093155–01
< Figures 4, 7, and 13 in grant application
HL068509–01A1.
Dr. Smart has entered into a Voluntary
Exclusion Agreement and has voluntarily
agreed for a period of seven (7) years,
beginning on October 23, 2012:
(1) To exclude himself from any
contracting or subcontracting with any
agency of the United States Government and
from eligibility or involvement in
nonprocurement programs of the United
States Government referred to as ‘‘covered
transactions’’ pursuant to HHS’
Implementation (2 CFR part 376 et seq.) of
OMB Guidelines to Agencies on
Govermentwide Debarment and Suspension,
2 CFR part 180 (collectively the ‘‘Debarment
Regulations’’);
(2) To exclude himself voluntarily from
serving in any advisory capacity to PHS
including, but not limited to, service on any
PHS advisory committee, board, and/or peer
review committee, or as a consultant; and
(3) To request that the following
publications be retracted or corrected: J. Biol.
Chem. 277(7):4925–31, 2002; Am J. Physiol.
Cell Physiol. 291(6):C1271–8, 2006; Am J.
Physiol. Cell Physiol. 294(1):C295–305, 2008;
J. Lipid Res. 42:1444–1449, 2001; J. Biol.
Chem. 275:25595, 2000; J. Biol. Chem.
277(26):23525–33, 2002; Proc. Natl. Acad.
Sci. USA 101(10):3450–5, 2004; J. Biol. Chem.
280(33):29543–50, 2005; J. Biol. Chem.
273:6525–6532, 1998; Am J. Physiol. Cell
Physiol. 282:C935–46, 2002.
FOR FURTHER INFORMATION CONTACT:
Director, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8200.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Request for Nominations for
Candidates To Serve on the National
Public Health Surveillance and
Biosurveillance Advisory Committee
(NPHSBAC)
Correction: This notice was published
in the Federal Register on November 6,
2012, Volume 77, Number 215, page
66620. Paragraphs three through six of
the notice should read as follows:
Federal employees will not be
considered for membership. Members
may be invited to serve up to four-year
terms. Consideration is given to
representation from diverse geographic
areas, both genders, all ethnic and racial
groups, and the disabled. Nominees
must be U.S. citizens.
The following information must be
submitted for each candidate: name,
affiliation, address, telephone number,
and current curriculum vitae. Email
addresses are requested if available.
Nominations should be sent, in
writing, and postmarked by November
30, 2012 to: Vernellia Johnson,
Management and Program Analyst,
Public Health Surveillance and
Informatics Program Office, Centers for
Disease Control and Prevention, Office
of Surveillance, Epidemiology and
Laboratory Services, 1600 Clifton Road
NE., MS E–97, Atlanta, Georgia 30333 or
via email to hft9@cdc.gov. Telephone
and facsimile submissions cannot be
accepted.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Dated: November 13, 2012.
Elaine L. Baker,
Director, Management Analysis and Services
Office Centers for Disease Control and
Prevention.
[FR Doc. 2012–28172 Filed 11–19–12; 8:45 am]
BILLING CODE 4163–18–P
David E. Wright,
Director, Office of Research Integrity.
[FR Doc. 2012–28209 Filed 11–19–12; 8:45 am]
BILLING CODE 4150–31–P
PO 00000
Frm 00039
Fmt 4703
Sfmt 9990
E:\FR\FM\20NON1.SGM
20NON1
]]>Agencies
[Federal Register Volume 77, Number 224 (Tuesday, November 20, 2012)]
[Notices]
[Page 69628]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-28172]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Request for Nominations for Candidates To Serve on the National
Public Health Surveillance and Biosurveillance Advisory Committee
(NPHSBAC)
Correction: This notice was published in the Federal Register on
November 6, 2012, Volume 77, Number 215, page 66620. Paragraphs three
through six of the notice should read as follows:
Federal employees will not be considered for membership. Members
may be invited to serve up to four-year terms. Consideration is given
to representation from diverse geographic areas, both genders, all
ethnic and racial groups, and the disabled. Nominees must be U.S.
citizens.
The following information must be submitted for each candidate:
name, affiliation, address, telephone number, and current curriculum
vitae. Email addresses are requested if available.
Nominations should be sent, in writing, and postmarked by November
30, 2012 to: Vernellia Johnson, Management and Program Analyst, Public
Health Surveillance and Informatics Program Office, Centers for Disease
Control and Prevention, Office of Surveillance, Epidemiology and
Laboratory Services, 1600 Clifton Road NE., MS E-97, Atlanta, Georgia
30333 or via email to hft9@cdc.gov. Telephone and facsimile submissions
cannot be accepted.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities for
both the Centers for Disease Control and Prevention and the Agency for
Toxic Substances and Disease Registry.
Dated: November 13, 2012.
Elaine L. Baker,
Director, Management Analysis and Services Office Centers for Disease
Control and Prevention.
[FR Doc. 2012-28172 Filed 11-19-12; 8:45 am]
BILLING CODE 4163-18-P
